Avalo Therapeutics AVTX Proceeds From Warrant Exercises
Proceeds From Warrant Exercises at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.
The official record: Avalo Therapeutics’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's proceeds from warrant exercises.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's proceeds from warrant exercises?
- Avalo Therapeutics (AVTX) reported proceeds from warrant exercises of $0 in Q4 2025.
- How has Avalo Therapeutics's proceeds from warrant exercises changed year-over-year?
- Avalo Therapeutics's proceeds from warrant exercises decreased by 100.0% year-over-year, from $17.34M to $0.
- What does proceeds from warrant exercises mean?
- Captures the cash received by the company when holders of warrants exercise their right to purchase common stock at a predetermined strike price. This represents a non-dilutive source of capital that occurs when the company's stock price exceeds the warrant exercise price. It serves as an indicator of both historical financing success and potential future dilution for existing shareholders.